InflaRx N.V. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
IFRX Nasdaq 2836 www.inflarx.de

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for InflaRx N.V.

InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation - Jan 8th, 2026 6:00 am
InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum - Dec 30th, 2025 5:30 am
InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904 - Dec 11th, 2025 5:30 am
Microscopic Polyangiitis Market Research Report 2025-2035, Competitive Analysis of Roche, Amgen, Teva, Novartis, Baxter, Amerigen Pharma, InflaRx, Biogen, Pfizer, Celltrion - Nov 18th, 2025 8:20 am
InflaRx (IFRX) Is Up 17.7% After INF904 Shows Promising Results in Phase 2a Study—What's Changed - Nov 12th, 2025 7:10 pm
BC-Most Active Stocks - Nov 10th, 2025 8:30 am
InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU) - Nov 10th, 2025 5:30 am
InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria - Nov 7th, 2025 2:05 pm
Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Beat Estimates - Nov 5th, 2025 3:35 pm
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates - Nov 4th, 2025 6:15 am
InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference - Oct 21st, 2025 5:20 am
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement - Sep 12th, 2025 6:30 am
InflaRx Announces Participation in September Investor Conferences - Aug 21st, 2025 5:30 am
InflaRx N.V. (IFRX) Reports Q2 Loss, Misses Revenue Estimates - Aug 7th, 2025 6:45 am
InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update - Aug 7th, 2025 5:30 am
Axsome Therapeutics (AXSM) Reports Q2 Loss, Beats Revenue Estimates - Aug 4th, 2025 6:10 am
Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans? - Jul 31st, 2025 7:00 am
InflaRx to Report Second Quarter 2025 Results on August 7, 2025 - Jul 31st, 2025 5:30 am
InflaRx Discontinues Pyoderma Gangrenosum Trial, Shifts Focus to INF904 with Summer 2025 Data Expected - Jul 25th, 2025 10:22 am
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - Jul 11th, 2025 2:15 pm